Following these transactions, Bobo holds 46,935.7184 shares directly, with additional holdings in indirect accounts, including 38,616.6145 shares in a 401(k) and 135,152 shares held by a trust. The company maintains robust financial health with a current ratio of 3.46 and an impressive gross profit margin of 76.6%. The company maintains robust financial health with a current ratio of 3.46 and an impressive gross profit margin of 76.6%.
Following these transactions, Bobo holds 46,935.7184 shares directly, with additional holdings in indirect accounts, including 38,616.6145 shares in a 401(k) and 135,152 shares held by a trust. The company maintains robust financial health with a current ratio of 3.46 and an impressive gross profit margin of 76.6%.
Following these transactions, Bobo holds 46,935.7184 shares directly, with additional holdings in indirect accounts, including 38,616.6145 shares in a 401(k) and 135,152 shares held by a trust.
In other recent news, Edwards Lifesciences (NYSE:) has been the focus of several analyst adjustments. Wolfe Research has downgraded Edwards Lifesciences’ stock rating to Underperform, citing concerns over growth prospects compared to peers. However, the company maintains a “GREAT” financial health score and has achieved impressive revenue growth of 24.02% in the last twelve months. Jefferies has maintained a Hold rating, noting a year-over-year revenue decline of 2.7% for November 2024 in the U.S. TAVR market. Despite this, the firm reports that U.S. TAVR revenue for the fourth quarter to date has grown by 6.5%, surpassing the consensus estimate of 4% growth.
RBC Capital Markets projects a favorable outlook for the Medical (TASE:) Supplies & Devices sector for 2025, identifying significant upside opportunities in stocks such as Edwards Lifesciences. The firm’s surveys indicate potential market growth for the company, particularly in transcatheter valve therapies. BofA Securities upgraded Edwards Lifesciences from a Neutral to a Buy rating and increased the price target to $90 from the previous $82, anticipating a positive trajectory for the company’s stock in 2025, driven by multiple potential catalysts and the strategic importance of its TAVR technology.
Lastly, TD Cowen maintained a Hold rating on Edwards Lifesciences’ stock after the company presented a favorable multiyear outlook. The company reiterated its 2024 guidance and introduced its 2025 projections, including a return to double-digit annual revenue growth and sustaining double-digit growth in earnings per share.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
